Ivana Franke

 

Albrecht Hasinger Lecture 2016

Mary B. Goldring, PhD

Hospital for Special Surgery und Weill Cornell Medical College, New York City, NY, USA

„Die schwierige Suche nach einem Target in der Osteoarthritis-Therapie: Was wir von In-vitro- und In-vivo-Modellen lernen können“

Mary Goldring

Mary B. Goldring, PhD, ist Senior Scientist und Kodirektorin des Programms für Gewebe-Engineering, -Regeneration und -Reparatur an der Forschungsabteilung des Hospital for Special Surgery und Professorin für Zell- und Entwicklungsbiologie am Weill Cornell Medical College in New York City. In ihrer Arbeit auf dem Gebiet der Knorpelbiologie befasst sie sich schwerpunktmäßig mit der molekularen Regulierung des Umbaus der extrazellulären Matrix. Zu ihren wichtigsten Forschungsbeiträgen gehören die Identifizierung von molekularen und zellulären Mechanismen, die an der Pathogenese von Osteoarthritis und rheumatoider Arthritis beteiligt sind, sowie die Entwicklung von In-vitro-Modellen für das Studium der Biologie menschlicher Chondrozyten. Aktuell geht sie der Frage nach, wie sich Erkenntnisse aus der Osteoarthritis-Forschung mit Mäusen auf Krankheitsaspekte beim Menschen übertragen lassen.

Anlässlich der Albrecht Hasinger Lecture 2016 spricht Mary B. Goldring über Die schwierige Suche nach einem Target in der Osteoarthritis-Therapie: Was wir von In-vitro- und In-vivo-Modellen lernen können“ (auf Englisch):

“Osteoarthritis (OA) is a whole joint disease, in which thinning and loss of cartilage is a critical determinant in OA progression. The disruption of cartilage homeostasis due to multiple potential causes, related to aging, genetic predisposition, trauma, or metabolic disorder, is associated with profound phenotypic modifications of chondrocytes. Early changes involve disruption of the pericellular matrix through signaling events mediated by chondrocyte receptors such as discoidin domain receptor-2 (DDR-2) and syndecan-4. My laboratory studies the mechanisms of gene regulation by which stress- and inflammation-induced signals induce expression of matrix metalloproteinase 13 (MMP-13), the pivotal collagen-degrading proteinase that marks osteoarthritis progression, as well as other catabolic and anabolic responses in cartilage and other joint tissues. Common mediators of these processes in human OA cartilage are also involved in mechano-transduction, including the protein kinases, IKKs and MAPKs. These pathways converge on transcriptional regulation of MMP13, IL1B, and other key genes by NF-kB, Elf3, C/EBPb, Runx2, and hypoxia-inducible factor (HIF) 2a. Alterations in the methylation status of specific CpG sites in the promoters of MMP13, IL1B, NOS2, and COL9A1 are also associated with aberrant gene expression in OA cartilage. Current work involves relating findings in mouse models of osteoarthritis to aspects of the human disease by examining knockout and transgenic mouse strains in the context of a post-traumatic OA mouse model due to surgical destabilization of the medial meniscus (DMM). Novel mouse strains have been generated in which the cytokine-inducible transcription factor Elf3 is either knocked out specifically in cartilage (Col2a1Cre;Elf3fl/fl) or overexpressed in cartilage and synovium (Comp-tTA;TRE-Elf3). Current efforts are profiling gene expression (RNAseq) and microRNAs over the course of disease initiation and progression in novel mouse strains with inducible, cartilage-specific deletion of the NF-kB signaling kinases, IKKa and IKKb, compared to the Runx2+/- mouse, which is protected from DMM-OA, and the Col11a1+/- (Cho/+; chondrodysplasia) mouse that develops accelerated OA with aging. Since the chondrocytes in adult human cartilage are normally quiescent and maintain the matrix in a low turnover state, understanding how they undergo phenotypic modulation and participate in matrix destruction and abnormal repair in OA may lead to identification of critical targets for therapy to block cartilage damage and promote effective cartilage repair.” [Mary B. Goldring]

Festveranstaltung am 6. Dezember 2016, 17:00 Uhr

Die von der Schering Stiftung geförderte Albrecht Hasinger Lecture findet in Verbindung mit der Verleihung des Avrion-Mitchison-Preises am Deutschen Rheuma-Forschungszentrum statt.

pdf Programm zum Download

Deutsches Rheuma-Forschungszentrum Berlin
Campus Charité Mitte

Charitéplatz 1
10117 Berlin

www.drfz.de